{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:45:24Z","timestamp":1790239524259,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2004,6,1]]},"DOI":"10.1038\/sj.leu.2403351","type":"journal-article","created":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T10:17:55Z","timestamp":1080814675000},"page":"1072-1077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"18","author":[{"given":"L J","family":"Hak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M V","family":"Relling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J T","family":"Sandlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Rubnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-H","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,4,1]]},"reference":[{"key":"BF2403351_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM199808273390907","volume":"339","author":"C-H Pui","year":"1998","unstructured":"Pui C-H, Evans WE . Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605\u2013615.","journal-title":"N Engl J Med"},{"key":"BF2403351_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211\u20131218.","journal-title":"Blood"},{"key":"BF2403351_CR3","first-page":"365","volume-title":"Treatment of Acute Leukemias. New Directions for Clinical Research","author":"BL Asselin","year":"2003","unstructured":"Asselin BL, Kurtzberg J . Asparaginase. In: Pui C-H (ed) Treatment of Acute Leukemias. New Directions for Clinical Research. Totowa, NJ: Humana Press, 2003, pp 365\u2013379."},{"key":"BF2403351_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJM198609113151101","volume":"315","author":"LA Clavell","year":"1986","unstructured":"Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell JN et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315: 657\u2013683.","journal-title":"N Engl J Med"},{"key":"BF2403351_CR5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.7326\/0003-4819-74-6-893","volume":"74","author":"RL Capizzi","year":"1971","unstructured":"Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893\u2013901.","journal-title":"Ann Intern Med"},{"key":"BF2403351_CR6","first-page":"4363","volume":"49","author":"BL Asselin","year":"1989","unstructured":"Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P, Sallan SE et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989; 49: 4363\u20134368.","journal-title":"Cancer Res"},{"key":"BF2403351_CR7","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","volume":"11","author":"BL Asselin","year":"1993","unstructured":"Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen JH . Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780\u20131786.","journal-title":"J Clin Oncol"},{"key":"BF2403351_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1172\/JCI106579","volume":"50","author":"RG Peterson","year":"1971","unstructured":"Peterson RG, Hanschumacher RE, Mitchell MS . Immunological responses to L-asparaginase. J Clin Invest 1971; 50: 1080\u20131090.","journal-title":"J Clin Invest"},{"key":"BF2403351_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/10428199309149129","volume":"10","author":"MJ Keating","year":"1993","unstructured":"Keating MJ, Holmes R, Lerner S, Ho DH . L-asparaginase and PEG asparaginase-past, present, and future. Leukemia Lymphoma 1993; 10: 153\u2013157.","journal-title":"Leukemia Lymphoma"},{"key":"BF2403351_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U","volume":"25","author":"HF Oettgen","year":"1970","unstructured":"Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallal L, Tan CC et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25: 253\u2013278.","journal-title":"Cancer"},{"key":"BF2403351_CR11","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/sj.leu.2401162","volume":"12","author":"MH Woo","year":"1998","unstructured":"Woo MH, Hak LJ, Storm MC, Sandlund JR, Ribeiro RC, Rivera GK et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527\u20131533.","journal-title":"Leukemia"},{"key":"BF2403351_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W","volume":"37","author":"D Killander","year":"1976","unstructured":"Killander D, Dohlwitz A, Engstedt L, Franzen S, Gahrton G, Gullbring B et al. Hypersensitivity reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976; 37: 220\u2013228.","journal-title":"Cancer"},{"key":"BF2403351_CR13","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2003.07.056","volume":"21","author":"S Kishi","year":"2003","unstructured":"Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084\u20133091.","journal-title":"J Clin Oncol"},{"key":"BF2403351_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0022-1759(00)00182-4","volume":"239","author":"B Wang","year":"2000","unstructured":"Wang B, Hak LJ, Relling MV, Pui C-H, Woo MH, Storm MC . Elisa to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods 2000; 239: 75\u201383.","journal-title":"J Immunol Methods"},{"key":"BF2403351_CR15","volume-title":"Nonparametrics: Statistical Methods Based on Ranks","author":"EL Lehmann","year":"1975","unstructured":"Lehmann EL . Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA: Holden-Day, Inc., 1975, 51pp."},{"key":"BF2403351_CR16","volume-title":"An Introduction Categorical Data Analysis","author":"A Agresti","year":"1996","unstructured":"Agresti A . An Introduction Categorical Data Analysis. New York, NY: John Wiley & Sons, Inc., 1996, 39pp."},{"key":"BF2403351_CR17","first-page":"5601","volume":"43","author":"SE Sallan","year":"1983","unstructured":"Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan DG . Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983; 43: 5601\u20135607.","journal-title":"Cancer Res"},{"key":"BF2403351_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","volume":"96","author":"E Ahlke","year":"1997","unstructured":"Ahlke E, Nowak-Gottl U, Schulze-Westhott P, Werber G, Borste H, Wurthwein G et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamics control during induction therapy in children with acute lymphoblastic leukemia. Br J Haematol 1997; 96: 675\u2013681.","journal-title":"Br J Haematol"},{"key":"BF2403351_CR19","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","volume":"32A","author":"J Boos","year":"1996","unstructured":"Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Gottl U, Wurthwein G et al. Monitoring of asparaginase activity and asparagines levels in children on different asparaginase preparations. Eur J Can 1996; 32A: 1544\u20131550.","journal-title":"Eur J Can"},{"key":"BF2403351_CR20","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V96.5.1709","volume":"96","author":"TC Abshire","year":"2000","unstructured":"Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR . Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood 2000; 96: 1709\u20131715.","journal-title":"Blood"},{"key":"BF2403351_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","volume":"18","author":"MH Woo","year":"2000","unstructured":"Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK et al. Hypersensitivity or development of antibodies of asparaginase do not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1525\u20131532.","journal-title":"J Clin Oncol"},{"key":"BF2403351_CR22","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/sj.leu.2403011","volume":"17","author":"B Wang","year":"2003","unstructured":"Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui C-H et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003; 17: 1583\u20131588.","journal-title":"Leukemia"},{"key":"BF2403351_CR23","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periciou AP, Hather H, Bostrom BC, Cohen LJ et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99: 1986\u20131994.","journal-title":"Blood"},{"key":"BF2403351_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1055\/s-2007-1000660","volume":"21","author":"LG Mitchell","year":"1995","unstructured":"Mitchell LG, Sutor AH, Andrew M . Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Throm Hemostasis 1995; 21: 390\u2013401.","journal-title":"Semin Throm Hemostasis"},{"key":"BF2403351_CR25","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood.V93.5.1595","volume":"93","author":"U Nowak-Gottl","year":"1999","unstructured":"Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93: 1595\u20131599.","journal-title":"Blood"},{"key":"BF2403351_CR26","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","volume":"99","author":"M Duval","year":"2002","unstructured":"Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer \u2013 Children's Leukemia Group phase 3 trial. Blood 2002; 99: 2734\u20132739.","journal-title":"Blood"},{"key":"BF2403351_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0268-9499(94)90249-6","volume":"8","author":"U Nowak-Gottl","year":"1994","unstructured":"Nowak-Gottl U, Boos J, Wolff JEA, Erber G, Ahlke E, Pollmann H et al. Influence of two different E. coli asparaginase preparations on coagulation and fibrinolysis: a randomized trial. Fibrinolysis 1994; 8: 66.","journal-title":"Fibrinolysis"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403351","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:43:59Z","timestamp":1648777439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6,1]]}},"alternative-id":["BF2403351"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403351","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,1]]},"assertion":[{"value":"19 January 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}